If you're looking for an investment in the pharmaceutical sector and you don't already own shares of (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of highly technological cancer therapies is almost certain to expand over time, and its pipeline is packed with candidates for next-generation medicines. Many of those candidates will likely get their shot at approval by regulators.

So let's see where Amgen -- and its investors -- could be three years from now as there's plenty of evidence suggesting the future looks bright.

The next three years will be significantly different from the recent past, which will be a relief to shareholders. Over the last three years, Amgen's quarterly operating income crashed by more than 57%, reaching $991 million. Management attributes the decline to higher expenses related to one of its recent acquisitions, so it shouldn't be as much of a future factor.

Continue reading

Source Fool.com